Winship Cancer Institute of Emory University (105) Trials

Winship Cancer Institute of Emory University (105)	Welcome, Profile Billing Logout

Winship Cancer Institute of Emory University (105)

Welcome, Profile Billing Logout

0 Trials

2 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Sterling, Marsha

IO-202-CL-001, NCT04372433: IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

Active, not recruiting

106

IO-202, IO-202 and Azacitidine, IO-202 and AZA, IO-202 and Azacitidine + Venetoclax, IO-202 and AZA + Ven

Immune-Onc Therapeutics, California Institute for Regenerative Medicine (CIRM)

AML With Monocytic Differentiation, CMML

01/26

01/27

STK-012-101, NCT05098132: STK-012 Monotherapy and in Combination Therapy in Patients with Solid Tumors

Recruiting

202

STK-012, pembrolizumab, pemetrexed, carboplatin

Synthekine

Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Cervical Cancer, Microsatellite Instability High, Gastric Cancer, GastroEsophageal Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency

10/27

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites